RenovoRx Inc

Research RenovoRx Inc (RNXT) on Bullrun: market cap USD 43.75M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRNXT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 43.75M
• Financial periodFY2025
• RevenueUSD 1.12M
• Revenue growth2511.6%
• Net income-USD 11.17M
• Free cash flow-USD 10.98M
• Gross margin70.9%

Valuation Snapshot

latest market cap is USD 43.75M.

About RenovoRx Inc

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Frequently asked questions

What is RenovoRx Inc's market cap?

RenovoRx Inc's market capitalization is USD 43.75M.

What does RenovoRx Inc do?

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.